Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: FYI Swartz...

Not a 1:1 for all warrants... but probably fairly close...

From the '07 10K:

Recent Sale of Unregistered Securities

Unless otherwise noted, the issuances noted below are all considered exempt from registration by reason on Section 4(2) of the Securities Act of 1933, as amended.
On August 14, 2006 warrants to purchase 150,000 shares of our common stock were exercised by an investor for proceeds of $60,000.
The exercises listed below were performed on a cashless basis. By exercising on a cashless basis, the warrant holder authorizes us to withhold from issuance shares of common stock that would otherwise be issuable upon exercise of the warrant which when multiplied by the market price of the common stock as of the date of exercise is equal to the aggregate exercise price. The market price, as defined in the warrant, is the volume weighted average price (“VWAP”) of our common stock during the 10 consecutive trading day period immediately preceding the date of exercise, less the exercise price of the warrant, this product is then divided by the VWAP and the result is multiplied by the number of shares in the warrant to arrive at the net number of shares to issue.
On June 8, 2006 warrants to purchase 1,366,727 shares of our common stock at an exercise price of $0.015 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 17,780, an aggregate value of $17,549, based on a VWAP of $1.153 as of the exercise date. Accordingly, we issued 1,348,947 shares of our common stock upon the exercise.
On June 8, 2006 warrants to purchase 690,211 shares of our common stock at an exercise price of $0.04 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 25,948, an aggregate value of $24,973, based on a VWAP of $1.064 as of the exercise date. Accordingly, we issued 664,263 shares of our common stock upon the exercise.
On October 17, 2006 warrants to purchase 6,951,428 shares of our common stock at an exercise price of $0.03363 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 219,344, an aggregate value of $212,423, based on a VWAP of $1.0658 as of the exercise date. Accordingly, we issued 6,732,084 shares of our common stock upon the exercise.
On October 17, 2006 warrants to purchase 8,035,192 shares of our common stock at an exercise price of $0.0399 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 300,811, an aggregate value of $289,550, based on a VWAP of $1.0658 as of the exercise date. Accordingly, we issued 7,734,381 shares of our common stock upon the exercise.
On October 20, 2006 warrants to purchase 2,692,308 shares of our common stock at an exercise price of $0.015 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 37,916, an aggregate value of $37,382, based on a VWAP of $1.0651 as of the exercise date. Accordingly, we issued 2,654,392 shares of our common stock upon the exercise.
12
On October 20, 2006 warrants to purchase 2,307,692 shares of our common stock at an exercise price of $0.015 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 32,499, an aggregate value of $32,041, based on a VWAP of $1.0651 as of the exercise date. Accordingly, we issued 2,275,193 shares of our common stock upon the exercise.
On March 19, 2007 warrants to purchase 9,431,137 shares of our common stock at an exercise price of $0.0167 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 247,681, an aggregate value of $241,176, based on a VWAP of $0.6359 as of the exercise date. Accordingly, we issued 9,183,456 shares of our common stock upon the exercise.
On March 19, 2007 warrants to purchase 1,271,106 shares of our common stock at an exercise price of $0.015 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 29,984, an aggregate value of $29,277, based on a VWAP of $0.6359 as of the exercise date. Accordingly, we issued 1,241,122 shares of our common stock upon the exercise.
On May 24, 2007 warrants to purchase 2,142,857 shares of our common stock at an exercise price of $0.035 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 148,251, an aggregate value of $137,994, based on a VWAP of $0.5059 as of the exercise date. Accordingly, we issued 1,994,606 shares of our common stock upon the exercise.
On May 24, 2007 warrants to purchase 4,000,000 shares of our common stock at an exercise price of $0.025 were exercised by an investor on a cashless basis. The number of shares of common stock that would otherwise have been issuable upon the exercise of such warrants was reduced by 197,668, an aggregate value of $187,900, based on a VWAP of $0.5059 as of the exercise date. Accordingly, we issued 3,802,332 shares of our common stock upon the exercise.
regards
Share
New Message
Please login to post a reply